Literature DB >> 28520216

Evaluation of Prediction of Polymorphisms of DNA Repair Genes on the Efficacy of Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer: A Network Meta-Analysis.

Shao-Nan Yu1, Gui-Feng Liu1, Xue-Feng Li2, Bao-Hong Fu1, Li-Xin Dong2, Shu-Hua Zhang3.   

Abstract

This network meta-analysis (NMA) was conducted to compare the predictive value of 14 SNPs in eight DNA repair genes on the efficacy of platinum-based chemotherapy in patients with non-small cell lung cancer (NSCLC). These included ERCC1 (rs11615, rs3212986, rs3212948), XRCC1 (rs25487, rs25489, rs1799782), XPD (rs13181, rs1799793), XPG (rs1047768, rs17655), XPA (rs1800975), XRCC3 (rs861539), APE1 (rs3136820), and RRM1 (rs1042858). The PubMed and Cochrane library databases were reviewed from their inception to February 2017 and studies which met our inclusion criteria were included in our investigation. This network meta-analysis combines direct and indirect evidence to assess the predictive value of 14 SNPs in eight DNA repair genes on the efficacy of platinum-based chemotherapy in NSCLC. We evaluated the predictive value through the use of the odd ratios (OR) and drawing surface under the cumulative ranking curves (SUCRA). A total of 26 eligible cohort studies were enrolled in this NMA. The pairwise meta-analysis indicated that in terms of overall response ratio (ORR), ERCC1 (rs11615), XRCC1 (rs25487, rs1799782), and XPD (rs13181) polymorphisms are associated with the efficacy of platinum-based chemotherapy in NSCLC. The result of this NMA suggests that there is no significant difference in predictive value of 8 DNA repair genes on the efficacy of platinum-based chemotherapy in NSCLC patients. The rank of SUCRA values of the 14 SNPs in the eight DNA repair genes were: XPD (rs1799793)→ERCC1 (rs3212986)→XPA(rs1800975)→ERCC1(rs3212948)→XRCC1(rs25487)→XRCC3(rs861539)→APE1(rs3136820)→ERCC1(rs11615)→XRCC1(rs1799782)→RRM1(rs1042858)→XPD(rs13181)→XPG (rs1047768)→XPG(rs17655)→XRCC1(rs25489). ERCC1(rs11615), XRCC1(rs25487, rs1799782) and XPD(rs13181) polymorphisms were better predictors in evaluating the efficacy of platinum-based chemotherapy in NSCLC patients. J. Cell. Biochem. 118: 4782-4791, 2017.
© 2017 Wiley Periodicals, Inc. © 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  DNA REPAIR GENE; NON-SMALL CELL LUNG CANCER; PLATINUM-BASED CHEMOTHERAPY; POLYMORPHISM; PREDICTION

Mesh:

Substances:

Year:  2017        PMID: 28520216     DOI: 10.1002/jcb.26147

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  6 in total

Review 1.  Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.

Authors:  Huan Tao; Yueyuan Zhang; Qian Li; Jin Chen
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-05       Impact factor: 4.553

2.  Architecture of The Human Ape1 Interactome Defines Novel Cancers Signatures.

Authors:  Dilara Ayyildiz; Giulia Antoniali; Chiara D'Ambrosio; Giovanna Mangiapane; Emiliano Dalla; Andrea Scaloni; Gianluca Tell; Silvano Piazza
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

3.  Polymorphisms in the BER and NER pathways and their influence on survival and toxicity in never-smokers with lung cancer.

Authors:  Ana Casal-Mouriño; Alberto Ruano-Ravina; María Torres-Durán; Isaura Parente-Lamelas; Mariano Provencio-Pulla; Olalla Castro-Añón; Iria Vidal-García; José Abal-Arca; María Piñeiro-Lamas; Alberto Fernández-Villar; Luis Valdés-Cuadrado; Juan Miguel Barros-Dios; Mónica Pérez-Ríos
Journal:  Sci Rep       Date:  2020-12-03       Impact factor: 4.379

4.  The association between XRCC3 rs1799794 polymorphism and cancer risk: a meta-analysis of 34 case-control studies.

Authors:  Weiqing Liu; Shumin Ma; Lei Liang; Zhiyong Kou; Hongbin Zhang; Jun Yang
Journal:  BMC Med Genomics       Date:  2021-04-30       Impact factor: 3.063

5.  Pharmacogenetic Association between XRCC1 Polymorphisms and Response to Platinum-Based Chemotherapy in Asian Patients with NSCLC: A Meta-Analysis.

Authors:  Ningning Zhang; Yushu Ouyang; Jianlan Chang; Ping Liu; Xiangyang Tian; Junyan Yu
Journal:  Biomed Res Int       Date:  2020-10-22       Impact factor: 3.411

6.  ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy.

Authors:  Maja Guberina; Ali Sak; Christoph Pöttgen; Ingeborg Tinhofer-Keilholz; Volker Budach; Panagiotis Balermpas; Jens Von der Grün; Claus Michael Rödel; Eleni Gkika; Anca-Ligia Grosu; Amir Abdollahi; Jürgen Debus; Claus Belka; Steffi Pigorsch; Stephani E Combs; David Mönnich; Daniel Zips; Chiara De-Colle; Stefan Welz; Annett Linge; Fabian Lohaus; Gustavo Baretton; Thomas Gauler; Michael Baumann; Mechthild Krause; Martin Schuler; Agnes Bankfalvi; Benedikt Höing; Stephan Lang; Martin Stuschke
Journal:  Pharmacogenomics J       Date:  2020-06-16       Impact factor: 3.550

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.